We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RadNet (RDNT) Soars 9.7%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
RadNet (RDNT - Free Report) shares ended the last trading session 9.7% higher at $80.26. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.1% gain over the past four weeks.
RadNet recorded a strong price rise on investors’ optimism surrounding its impending third-quarter 2026 financial results, slated to release on Nov. 9. In the previous quarter, the company’s revenue increased 25% year over year, with the Digital Health segment growing 56.5%. RadNet also signed new business with Total Contract Value of nearly $21 million, bringing its six-month new business Total Contract Value to approximately $37 million.
This operator of medical diagnostic imaging centers is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of +5%. Revenues are expected to be $637.56 million, up 21.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For RadNet, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RDNT going forward to see if this recent jump can turn into more strength down the road.
RadNet belongs to the Zacks Medical - Outpatient and Home Healthcare industry. Another stock from the same industry, Aveanna Healthcare (AVAH - Free Report) , closed the last trading session 7.2% higher at $14.23. Over the past month, AVAH has returned 8.7%.
For Aveanna, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.2. This represents a change of +33.3% from what the company reported a year ago. Aveanna currently has a Zacks Rank of #2 (Buy).
View the Zacks #1 Rank List
Image: Bigstock
RadNet (RDNT) Soars 9.7%: Is Further Upside Left in the Stock?
RadNet (RDNT - Free Report) shares ended the last trading session 9.7% higher at $80.26. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.1% gain over the past four weeks.
RadNet recorded a strong price rise on investors’ optimism surrounding its impending third-quarter 2026 financial results, slated to release on Nov. 9. In the previous quarter, the company’s revenue increased 25% year over year, with the Digital Health segment growing 56.5%. RadNet also signed new business with Total Contract Value of nearly $21 million, bringing its six-month new business Total Contract Value to approximately $37 million.
This operator of medical diagnostic imaging centers is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of +5%. Revenues are expected to be $637.56 million, up 21.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For RadNet, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RDNT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
RadNet belongs to the Zacks Medical - Outpatient and Home Healthcare industry. Another stock from the same industry, Aveanna Healthcare (AVAH - Free Report) , closed the last trading session 7.2% higher at $14.23. Over the past month, AVAH has returned 8.7%.
For Aveanna, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.2. This represents a change of +33.3% from what the company reported a year ago. Aveanna currently has a Zacks Rank of #2 (Buy).